NCT04711135 2026-02-12NETTER-PAdvanced Accelerator ApplicationsPhase 2 Active not recruiting11 enrolled 14 charts 1 FDA
NCT05997056 2024-07-16Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR InhibitorsAadi Bioscience, Inc.Phase 2 Recruiting21 enrolled
NCT03220217 2021-01-14To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)IpsenPhase 2 Completed29 enrolled 18 charts
NCT01994213 2019-01-22A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine TumorJiangsu HengRui Medicine Co., Ltd.Phase 2 Terminated53 enrolled